XTX Topco Ltd Invests $997,000 in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP)

XTX Topco Ltd acquired a new stake in shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) during the fourth quarter, according to its most recent disclosure with the SEC. The fund acquired 18,029 shares of the specialty pharmaceutical company’s stock, valued at approximately $997,000. XTX Topco Ltd owned approximately 0.09% of ANI Pharmaceuticals as of its most recent SEC filing.

A number of other hedge funds also recently made changes to their positions in ANIP. US Bancorp DE lifted its holdings in ANI Pharmaceuticals by 842.9% during the fourth quarter. US Bancorp DE now owns 594 shares of the specialty pharmaceutical company’s stock valued at $33,000 after purchasing an additional 531 shares in the last quarter. KBC Group NV lifted its stake in shares of ANI Pharmaceuticals by 89.2% during the 4th quarter. KBC Group NV now owns 1,273 shares of the specialty pharmaceutical company’s stock valued at $70,000 after buying an additional 600 shares in the last quarter. KLP Kapitalforvaltning AS bought a new position in ANI Pharmaceuticals in the 4th quarter worth $166,000. HighTower Advisors LLC bought a new position in ANI Pharmaceuticals in the 3rd quarter worth $222,000. Finally, China Universal Asset Management Co. Ltd. increased its stake in ANI Pharmaceuticals by 10.2% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 4,457 shares of the specialty pharmaceutical company’s stock worth $246,000 after buying an additional 412 shares in the last quarter. 76.05% of the stock is currently owned by institutional investors.

ANI Pharmaceuticals Price Performance

ANI Pharmaceuticals stock opened at $69.55 on Wednesday. ANI Pharmaceuticals, Inc. has a 52-week low of $52.50 and a 52-week high of $70.79. The company has a quick ratio of 1.97, a current ratio of 2.74 and a debt-to-equity ratio of 1.52. The firm’s fifty day moving average is $62.71 and its 200 day moving average is $59.22. The company has a market cap of $1.51 billion, a price-to-earnings ratio of -126.45 and a beta of 0.49.

Analyst Upgrades and Downgrades

A number of research firms have recently weighed in on ANIP. HC Wainwright reaffirmed a “buy” rating and issued a $94.00 price objective on shares of ANI Pharmaceuticals in a research note on Monday, March 17th. JPMorgan Chase & Co. began coverage on ANI Pharmaceuticals in a research note on Wednesday, March 12th. They issued an “overweight” rating and a $85.00 price target for the company. StockNews.com cut shares of ANI Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Tuesday, April 8th. Guggenheim restated a “buy” rating and set a $86.00 target price on shares of ANI Pharmaceuticals in a research report on Friday, April 11th. Finally, Jefferies Financial Group assumed coverage on shares of ANI Pharmaceuticals in a report on Friday, March 14th. They issued a “buy” rating and a $80.00 price target on the stock. One analyst has rated the stock with a sell rating, one has given a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $79.75.

Insider Transactions at ANI Pharmaceuticals

In other news, SVP Krista Davis sold 1,000 shares of ANI Pharmaceuticals stock in a transaction that occurred on Friday, March 7th. The stock was sold at an average price of $60.86, for a total value of $60,860.00. Following the completion of the transaction, the senior vice president now owns 66,525 shares in the company, valued at approximately $4,048,711.50. The trade was a 1.48 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, VP Meredith Cook sold 400 shares of the business’s stock in a transaction that occurred on Monday, April 14th. The shares were sold at an average price of $68.96, for a total value of $27,584.00. Following the transaction, the vice president now directly owns 80,145 shares in the company, valued at approximately $5,526,799.20. This represents a 0.50 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 3,200 shares of company stock worth $197,792 in the last three months. Insiders own 12.70% of the company’s stock.

ANI Pharmaceuticals Profile

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.